Accepted for Publication: February 16, 2018.
Corresponding Author: Michelle R. Lofwall, MD, Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Ave, Lexington, KY 40508 (michelle.lofwall@uky.edu).
Published Online: May 14, 2018. doi:10.1001/jamainternmed.2018.1052
Author Contributions: Drs Chen and Kim had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Lofwall, Walsh, Bailey, Frost, Tiberg, Linden, Sheldon, Oosman, Peterson, Chen, Kim.
Acquisition, analysis, or interpretation of data: Lofwall, Walsh, Nunes, Bailey, Sigmon, Kampman, Tiberg, Linden, Peterson, Chen, Kim.
Drafting of the manuscript: Lofwall, Walsh, Bailey, Sigmon, Kampman, Frost, Tiberg, Linden, Kim.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Lofwall, Walsh, Nunes, Tiberg, Peterson, Chen, Kim.
Obtained funding: Sheldon, Kim.
Administrative, technical, or material support: Walsh, Nunes, Bailey, Sigmon, Kampman, Linden, Oosman, Kim.
Study supervision: Tiberg, Sheldon, Oosman, Kim.
Conflict of Interest Disclosures: Dr Lofwall reported receiving research funding from Braeburn Pharmaceuticals, Inc, and consulting fees from Braeburn Pharmaceuticals, Inc, and Indivior. Dr Walsh reported receiving contract research funding and consulting fees from Braeburn Pharmaceuticals, Inc, consulting fees from Camurus AB, and travel support from Indivior. Dr Nunes reported receiving contract research funding from Braeburn Pharmaceuticals, Inc, Alkermes, Inc, and Brainsway, Inc, and unpaid consulting for Alkermes, Inc. Dr Bailey reported receiving research funding, advisory board, and traveling support from Braeburn Pharmaceuticals, Inc; advisory board, speaker bureau fees, and travel support from BioDelivery Science International, Inc, and Alkermes, Inc; and research funding and speaker fees from Indivior. Dr Kampman reported receiving research funding from Braeburn Pharmaceuticals, Inc, Indivior, and Opiant Pharmaceuticals, Inc. Dr Frost reported receiving research funding and consulting fees from Braeburn Pharmaceuticals, Inc; honorarium for talks from Indivior; and consulting fees and speaking honorarium from BioDelivery Sciences International, Inc. Drs Tiberg and Linden reported being employees of Camurus AB. Mss Sheldon and Oosman and Dr Kim reported being employees of Braeburn Pharmaceuticals, Inc. Dr Chen reported receiving consulting fees from Braeburn Pharmaceuticals, Inc. Dr Peterson reported receiving consulting fees from Camurus AB and AstraZeneca Ltd. No other disclosures were reported.
Funding/Support: The study was supported by Braeburn Pharmaceuticals, Inc, and by grant UL1TR001998 from the University of Kentucky Center for Clinical and Translational Science for research services and facilities for the study at this site.
Role of the Funder/Sponsor: Braeburn Pharmaceuticals, Inc, had a role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. They had no role in collection of the data.
1.Hedegaard
H, Warner
M, Minino
AM. Drug overdose deaths in the United States, 1999-2015.
NCHS Data Brief. 2017;(273):1-8.
PubMedGoogle Scholar 2.Rudd
RA, Seth
P, David
F, Scholl
L. Increases in drug and opioid-involved overdose deaths: United States, 2010-2015.
MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445-1452.
PubMedGoogle ScholarCrossref 3.Strathdee
SA, Beyrer
C. Threading the needle: how to stop the HIV outbreak in rural Indiana.
N Engl J Med. 2015;373(5):397-399.
PubMedGoogle ScholarCrossref 4.Schwartz
RP, McKenzie
M, Rich
JD. Opioid addiction and incarceration: an overview.
Med Health R I. 2007;90(5):157-158.
PubMedGoogle Scholar 5.Suryaprasad
AG, White
JZ, Xu
F,
et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.
Clin Infect Dis. 2014;59(10):1411-1419.
PubMedGoogle ScholarCrossref 8.Mattick
RP, Breen
C, Kimber
J, Davoli
M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Cochrane Database Syst Rev. 2014;(2):CD002207.
PubMedGoogle Scholar 10.Lofwall
MR, Walsh
SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
J Addict Med. 2014;8(5):315-326.
PubMedGoogle ScholarCrossref 11.Toce
MS, Burns
MM, O’Donnell
KA. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.
Clin Toxicol (Phila). 2017;55(1):12-17.
PubMedGoogle ScholarCrossref 12.Centers for Disease Control and Prevention (CDC). Emergency department visits and hospitalizations for buprenorphine ingestion by children: United States, 2010-2011.
MMWR Morb Mortal Wkly Rep. 2013;62(3):56.
PubMedGoogle Scholar 14.Volkow
ND, Frieden
TR, Hyde
PS, Cha
SS. Medication-assisted therapies: tackling the opioid-overdose epidemic.
N Engl J Med. 2014;370(22):2063-2066.
PubMedGoogle ScholarCrossref 15.Tiberg
F, Johnnson
M, Jankunec
M,
et al. Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions.
Chem Lett. 2012;41:1090-1092.
Google ScholarCrossref 16.Albayaty
M, Linden
M, Olsson
H, Johnsson
M, Strandgården
K, Tiberg
F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study.
Adv Ther. 2017;34(2):560-575.
PubMedGoogle ScholarCrossref 17.Rosenthal
RN, Lofwall
MR, Kim
S, Chen
M, Beebe
KL, Vocci
FJ; PRO-814 Study Group. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial.
JAMA. 2016;316(3):282-290.
PubMedGoogle ScholarCrossref 19.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
20.Mercer
D, Woody
G. Addiction counseling. [unpublished manual] Philadelphia: University of Pennsylvania/VAMC Center for Studies of Addiction; 1992.
21.Rosenthal
RN, Ling
W, Casadonte
P,
et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
Addiction. 2013;108(12):2141-2149.
PubMedGoogle ScholarCrossref 22.Krupitsky
E, Nunes
EV, Ling
W, Illeperuma
A, Gastfriend
DR, Silverman
BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Lancet. 2011;377(9776):1506-1513.
PubMedGoogle ScholarCrossref 23.Handelsman
L, Cochrane
KJ, Aronson
MJ, Ness
R, Rubinstein
KJ, Kanof
PD. Two new rating scales for opiate withdrawal.
Am J Drug Alcohol Abuse. 1987;13(3):293-308.
PubMedGoogle ScholarCrossref 24.Fals-Stewart
W, O’Farrell
TJ, Freitas
TT, McFarlin
SK, Rutigliano
P. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: psychometric properties.
J Consult Clin Psychol. 2000;68(1):134-144.
PubMedGoogle ScholarCrossref 25.Posner
K, Brown
GK, Stanley
B,
et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.
Am J Psychiatry. 2011;168(12):1266-1277.
PubMedGoogle ScholarCrossref 26.Dmitrienko
A, Offen
WW, Westfall
PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.
Stat Med. 2003;22(15):2387-2400.
PubMedGoogle ScholarCrossref 27.Weiss
RD, Potter
JS, Fiellin
DA,
et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Arch Gen Psychiatry. 2011;68(12):1238-1246.
PubMedGoogle ScholarCrossref 28.Weiss
RD, Potter
JS, Griffin
ML,
et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
Drug Alcohol Depend. 2015;150:112-119.
PubMedGoogle ScholarCrossref 29.Hser
YI, Evans
E, Huang
D,
et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Addiction. 2016;111(4):695-705.
PubMedGoogle ScholarCrossref 30.Hser
YI, Huang
D, Saxon
AJ,
et al. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone.
J Addict Med. 2017;11(1):63-69.
PubMedGoogle ScholarCrossref 31.Kampman
K, Jarvis
M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use.
J Addict Med. 2015;9(5):358-367.
PubMedGoogle ScholarCrossref 32.Fareed
A, Vayalapalli
S, Casarella
J, Drexler
K. Effect of buprenorphine dose on treatment outcome.
J Addict Dis. 2012;31(1):8-18.
PubMedGoogle ScholarCrossref 33.Hser
YI, Saxon
AJ, Huang
D,
et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Addiction. 2014;109(1):79-87.
PubMedGoogle ScholarCrossref 34.Ronan
MV, Herzig
SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12.
Health Aff (Millwood). 2016;35(5):832-837.
PubMedGoogle ScholarCrossref 35.D’Onofrio
G, O’Connor
PG, Pantalon
MV,
et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
JAMA. 2015;313(16):1636-1644.
PubMedGoogle ScholarCrossref 38.Kakko
J, Svanborg
KD, Kreek
MJ, Heilig
M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.
Lancet. 2003;361(9358):662-668.
PubMedGoogle ScholarCrossref